Revvity introduces GSP T1D 3plex kit for type 1 diabetes detection
Revvity launched the GSP T1D 3plex kit, a CE-IVDR-certified test for early type 1 diabetes detection in children. The kit uses dried blood samples and is available in Europe. The company aims to expand into child health screening and will present related services at an upcoming diabetes conference. Revvity also recently received FDA clearance for a testosterone test.
How this was made
The 30-second read
Why it matters
The launch introduces a new revenue stream but is geographically limited, suggesting a modest effect on Revvity's stock.
Market read
A new product launch that may incrementally boost Revvity's earnings outlook, primarily in European markets.
What to watch
Potential partnership with Sanofi could accelerate adoption; competition from other European diagnostic firms may limit market share.
Background
Revvity is expanding its diagnostics portfolio beyond newborn screening into pediatric diabetes detection.
Market effects
Strengthens Revvity's position in the diagnostics and newborn screening sector.
May boost European diagnostic equipment market activity.
Limited global impact as the kit is not FDA‑cleared.
Counterpoint
Without US FDA clearance, the product's revenue upside may be constrained and investors could remain cautious.
Key entities
- CompanyRevvity Inc.
US‑listed diagnostics and life‑science company.
- CompanySanofi
Partner for on‑site installation and off‑site testing services.
